



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/277,575-Conf. #3748
				Filing Date	March 27, 1999
				First Named Inventor	Newell et al.
				Art Unit	1644
				Examiner Name	F. P. Vandervegt
Sheet	1	of	2	Attorney Docket Number	V0139.70028US00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/PV/		US-4,971,951	11-20-1990	Garcia y Bellon et al.	
/PV/		US-5,286,653	02-15-1994	Brenner et al.	
/PV/		US-6,416,958-A1	07-09-2002	Vidovic et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
/PV/		EP-0524796	01-27-1993	Efamol Holdings PLC		
/PV/		WO-9716188	05-09-1997	Merck & Co., Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PV/		[No Author Listed] TAXOL Product Literature. Bristol Myers Squibb. 2003:1-6.			
		BERG et al., Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst. 1994 Jan 19;86(2):143-5.			
		BODMER et al., Identification of HLA-DP polymorphism with DP alpha and DP beta probes and monoclonal antibodies: correlation with primed lymphocyte typing. Proc Natl Acad Sci U S A. 1987 Jul;84(13):4596-600.			
		CARREL et al., Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol. 1985 Feb;15(2):118-23.			
		CRUMP et al., Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004 Oct 15;101(8):1835-42.			
		DEEN et al., A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature. 1988 Jan 7;331(6151):82-4.			
		FANCIULLI et al., Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. Oncol Res. 1996;8(3):111-20.			
		HEDLEY et al., Assembly and peptide binding of major histocompatibility complex class II heterodimers in an in vitro translation system. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10479-83.			
↓		HESS et al., A novel function of CD40: induction of cell death in transformed cells. J Exp Med. 1996 Jan 1;183(1):159-67.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

1166164.1


Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	09/277,575-Conf. #3748
				Filing Date	March 27, 1999
				First Named Inventor	Newell et al.
				Art Unit	1644
				Examiner Name	F. P. Vandervegt
Sheet	2	of	2	Attorney Docket Number	V0139.70028US00

/PVI/		HOON et al., Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. Cancer Res. 1991 Apr 15;51(8):2002-8.	
		IANNIELLO et al., Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial. Cancer. 1996 Jul 1;78(1):63-9.	
		KHOURY et al., Ex vivo treatment of antigen-presenting cells with CTLA4lg and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol. 1996 Oct 15;157(8):3700-5.	
		KUCHROO et al., B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995 Mar 10;80(5):707-18.	
		LAMARRE et al., Class II MHC molecules and the HIV gp 120 envelope protein interact with functionally distinct regions of the CD4 molecule. EMBO J. 1989 Nov;8(11):3271-7.	
		MIZUNO et al., The proteolytic cleavage of protein kinase C isotypes, which generates kinase and regulatory fragments, correlates with Fas-mediated and 12-O-tetradecanoyl-phorbol-13-acetate-induced apoptosis. Eur J Biochem. 1997 Nov 15;250(1):7-18.	
		NEWELL et al., The effects of chemotherapeutics on cellular metabolism and consequent immune recognition. J Immune Based Ther Vaccines. 2004 Feb 2;2(1):3.	
		POSADA et al., Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance. Cancer Commun. 1989;1(5):285-92.	
		STASSI et al., Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med. 1997 Oct 20;186(8):1193-200.	
		SUZUKI et al., Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2285-90.	
		TANSAN et al., Augmentation of vincristine cytotoxicity by megestrol acetate. Cancer Chemother Pharmacol. 1997;39(4):333-40.	
		UTZ et al., The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer. 1994 Apr 1;57(1):104-10.	
V		WANG et al., Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity. Anticancer Drugs. 1997 Oct;8(9):853-8.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/F Pierre Vandervegt/	Date Considered	10/29/2007
--------------------	-----------------------	-----------------	------------



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	09/277,575-Conf. #3748		
		Filing Date	March 27, 1999		
		First Named Inventor	Martha Karen Newell		
		Art Unit	1644		
		Examiner Name	F. P. Vandervegt		
Sheet	1	of	1	Attorney Docket Number	V0139.70028US00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/PVI/		BRYDER et al., Hematopoietic Stem Cells The Paradigmatic Tissue-Specific Stem Cell. Am J of Pathology. 2006 Aug; 169(2): 338-346		
/PVI/		ROLL et al., Regeneration of B Cell Subsets After Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis. Arthritis & Rheumatism. 2006 Aug; 54(8): 2377-2386		
/PVI/		WANG et al., Purified hematopoietic stem cells without facilitating cells can repopulate fully allogeneic recipients across entire major histocompatibility complex transplantation barrier in mice. Proc. Natl. Acad. Sci. 1997 Dec; Vol. 94: 14632-14636		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/F Pierre Vandervegt/	Date Considered	10/29/2007
-----------------------	-----------------------	--------------------	------------